NCT00162071终止2 期
"A Phase II Open-Label, Non-Randomized, Single-Center Trial to Determine the Optimal Myocardial Perfusion Image Acquisition Time Following BMS068645 Administration
Forest Laboratories1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2005年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Measurements of Technetium Tc99m Sestamibi activity will be obtained from various regions of the body at the end of the study to determine optimal imaging times.
研究概览
简要总结
The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Have known or suspected heart disease
- •Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days.
- •Weigh between 88 and 250 lbs.
排除标准
- •Allergic reaction to Technetium Tc99m Sestamibi or any of its components
- •History of asthma or lung disease
- •Ingestion of caffeinated substances within 12 hours prior to the study
结局指标
主要结局
Measurements of Technetium Tc99m Sestamibi activity will be obtained from various regions of the body at the end of the study to determine optimal imaging times.
次要结局
- A comparison of adverse events will be conducted at the end of the study to assess safety.
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator FiringHeart FailureNCT01085175Lantheus Medical Imaging
终止
2 期
Study of GPX-100 in the Treatment of Metastatic Breast CancerMetastasisBreast CancerNCT00123877Gem Pharmaceuticals40
已完成
2 期
Darusentan Effect on PET Uptake HeterogeneityEndothelial DysfunctionCoronary Artery DiseaseNCT00738049K.Lance Gould40
尚未招募
2 期
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSRare TumourNCT06692491Peking University Shenzhen Hospital200
终止
2 期
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast CancerBreast CancerNCT03697551Ipsen4